Keel Point’s Alnylam Pharmaceuticals ALNY Stock Holding History

Keel Point’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,387	Closed	-$202K	–	249
2020 Q3	$202K	Buy	+1,387	New	+$197K	0.02%	209

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Keel Point's ALNY Position: Q4 2020 in Review

Keel Point sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 1,387 shares — an estimated $202K sold.

Keel Point first reported a position in ALNY in Q3 2020 and held it in 1 quarter. The position peaked at $202K in Q3 2020. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

Keel Point reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Keel Point sold 1,387 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $202K.
Keel Point first reported a position in Alnylam Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Keel Point's Alnylam Pharmaceuticals position peaked at $202K in Q3 2020.
376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Keel Point's 13F filing for Q4 2020, filed 10 Feb 2021.